Cardiovascular Disease Doctors in Hannibal, MO Accepting Medicare

3 Cardiovascular Disease doctors found. Showing 1 - 3

Richard Paul Valuck Jr., M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6500 Hospital Dr, Hannibal, MO 63401 Phone: 573-629-3300    Fax: 573-629-3314

Dr. Shane Joseph Larue, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Dr, Hannibal, MO 63401 Phone: 573-231-3167    Fax: 573-221-1659

Allen J Duplantis, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6000 Hospital Drive, Hannibal, MO 63401 Phone: 573-248-1300

News Archive

Men undergoing circumcision may be at increased risk of infecting female partners with HIV

In the midst of an international campaign to slow the spread of HIV in sub-Saharan Africa, the World Health Organization recommends male circumcision (the surgical removal of foreskin from the penis) which reduces HIV acquisition by 50-60%.

Alcohol and antibiotics: an interview with Dr Randall

Contrary to popular belief, there are only a handful of antibiotics that can interact with alcohol to cause unpleasant effects. The two main antibiotics you should definitely avoid drinking alcohol with are metronidazole (brand names include Flagyl) and tinidazole (brand names include Fasigyn).

Companies providing home care receive large Medicare reimbursements

An analysis of Medicare payments to home health care companies by The Wall Street Journal indicates that some might be taking advantage of the system. According to the analysis, the industry's largest company, Amedisys Inc., "provided many of its patients just enough therapy visits to trigger the extra $2,200 payment.

FDA approves QIAGEN's therascreen EGFR test as companion diagnostic for NSCLC patients

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.

Researchers succeed in activating a 'single-molecule switch'

Everybody knows the force that is required to activate a light switch on a wall - a finger is enough. But how much force do you need to apply if the device was dramatically reduced to the "nanoscale world", that is, how much force do you need to operate a "single-molecule switch"? This fundamental question is related not only to basic science but also to potential future applications of molecular devices.

Read more Medical News

› Verified 4 days ago